Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
- DOI
- 10.1158/0008-5472.can-05-2050
- Published
- 2006 Jan 1
- Container
- Cancer research
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1158/0008-5472.can-05-2050,
title = {Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.},
author = {Schittenhelm MM and Shiraga S and Schroeder A and Corbin AS and Griffith D and Lee FY and Bokemeyer C and Deininger MW and Druker BJ and Heinrich MC},
year = {2006},
journal = {Cancer research},
doi = {10.1158/0008-5472.can-05-2050},
url = {https://doi.org/10.1158/0008-5472.can-05-2050}
}RIS
TY - JOUR TI - Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. AU - Schittenhelm MM AU - Shiraga S AU - Schroeder A AU - Corbin AS AU - Griffith D AU - Lee FY AU - Bokemeyer C AU - Deininger MW AU - Druker BJ AU - Heinrich MC PY - 2006 JO - Cancer research DO - 10.1158/0008-5472.can-05-2050 UR - https://doi.org/10.1158/0008-5472.can-05-2050 ER -
APA
MM, S., S, S., A, S., AS, C., D, G., FY, L., C, B., MW, D., BJ, D., & MC, H. (2006). Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.. Cancer research. https://doi.org/10.1158/0008-5472.can-05-2050
Source records
- pubmed · retrieved 2026-09-26T04:02:34.616Z